Summary & Overview
CPT 64615: Bilateral Chemical Denervation of Facial/Cervical Muscles
CPT code 64615 denotes bilateral chemical denervation of muscles innervated by the trigeminal, facial, cervical spinal, and accessory nerves, a procedure that produces targeted muscle paralysis. This intervention is clinically significant as a therapeutic option for conditions such as chronic migraine and other focal muscle hyperactivity disorders. Nationally, the code matters for ambulatory procedural billing, utilization monitoring, and coverage determinations tied to neuromuscular injection therapies.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise breakdown of clinical context and typical sites of service, plus the billing and policy implications that commonly arise for this type of procedure. The publication outlines benchmarks and reimbursement considerations, common payer coverage patterns, and practical coding elements associated with delivering bilateral chemical denervation under this CPT code.
The report provides guidance on where to find policy updates, common documentation and medical necessity themes that payers often require, and the clinical scenarios in which CPT code 64615 is applied. Data not available in the input will be clearly noted where applicable.
Billing Code Overview
CPT code 64615 describes bilateral chemical denervation of muscles innervated by the trigeminal, facial, cervical spinal, and accessory nerves with the intent to produce muscle paralysis. The procedure typically involves targeted injections of a neuromuscular blocking agent to reduce muscle activity in facial and head/neck muscle groups.
-
Service type: Therapeutic chemical denervation / neuromuscular injection for muscle paralysis, often used for chronic migraine management and other medically indicated focal muscle hyperactivity.
-
Typical site of service: Outpatient clinic, physician office, or ambulatory surgery center where injectable procedures are performed under appropriate monitoring; may also be performed in hospital outpatient settings depending on clinical context.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with a multi-year history of chronic migraine presents to a neurology clinic after inadequate response to oral preventive agents and monoclonal antibody therapy. The neurologist documents headache frequency of >15 days per month, with at least 8 days meeting migraine criteria despite optimized medical therapy. After counseling and informed consent, the provider schedules outpatient bilateral onabotulinumtoxinA injections targeting head and neck muscles innervated by trigeminal, facial, cervical spinal, and accessory nerves to induce temporary chemodenervation and reduce migraine frequency.
The clinical workflow includes pre-procedure assessment (history, medication review, informed consent), selection of target muscle groups (frontalis, corrugator, procerus, temporalis, occipitalis, cervical paraspinals, trapezius), aseptic preparation, bilateral injections with documented units and sites, post-procedure observation for immediate adverse effects, and instructions for follow-up at 4–12 weeks to assess response. Billing uses procedural code 64615 for bilateral administration and may include appropriate diagnosis codes for chronic migraine on the claim.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
50 | Bilateral procedure | Use when procedure is performed bilaterally if payer requires modifier for bilateral reporting; note description already denotes bilateral administration but some payers request for claims processing. |